An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies. An emerging class of anticancer drugs called EZH2 inhibitors may greatly ...
But the FDA’s decision does not preclude CMS from determining that the higher dose is not reasonable and necessary — ...
Researchers have developed a light-activated nanoassembly that helps anticancer drugs overcome multiple intracellular barriers and reach the cell nucleus more efficiently. This strategy significantly ...
BRCA1 and BRCA2 genes play a crucial role in repairing damaged DNA. Mutations in BRCA1 and BRCA2 substantially increase the likelihood of breast and ovarian cancer, respectively. This new research ...
A one‑year course of T‑DM1 offers excellent cancer‑free survival for early HER2‑positive breast cancer, with far less nerve ...
Opdivo, combined with chemotherapy, improved event-free survival in resectable non-small cell lung cancer, showing significant benefits over chemotherapy alone. Itovebi, combined with Ibrance and ...
Researchers have developed a human intestinal cell model that closely mimics the structure and function of the human gut, enabling more precise prediction of drug-induced gastrointestinal toxicity ...
Intestine-Mimicking Cell Model Accurately Predicts Drug Toxicity KRIBBs hIEC model detects gastrointestinal toxicity with 94% accuracy, offering early prediction of drug side effects ...
Vital chemotherapy drugs used around the world have failed quality tests, putting cancer patients in more than 100 countries at risk of ineffective treatments and potentially fatal side effects, an ...
Pretreatment with EZH2 inhibitor (top right) leads to higher recruitment of CAR-T cells (red) into the lymph node tumor compared with control (top left). Pretreatment with EZH2 inhibitor (bottom right ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results